[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraabdominal-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraabdominal-hypertension":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100593586","phase-3-the-role-of-intraabdominal-pressure-and-point-of-care-ultrasound-to-guide-decongestive-therapy-in-heart-failure-100593586",false,"NCT07008365","The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure","ABDOPOCUS-HF","Inclusion Criteria:\n\n* Men or women over 18 years of age.\n* Diagnosis of heart failure (HF) based on the latest HF guidelines published in 2022.\n* N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 1000 pg\u002FmL or Brain Natriuretic Peptide (BNP) \\> 250 pg\u002FmL.\n* Placement of a urinary catheter to allow for the measurement of intra-abdominal pressure.\n* Intravascular or mixed congestion pattern, defined as the presence of one or more clinical signs of congestion (edema, ascites, and\u002For pleural effusion).\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient with a stay in the Internal Medicine department \\> 24 hours.\n* Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization).\n* Patient\\'s refusal to participate in the clinical trial.\n* Inability or contraindication for urinary catheter placement.\n* Systolic blood pressure at admission \\< 100 mmHg.\n* Heart rate at admission \\> 170 beats per minute (bpm).\n* Cardiogenic shock.\n* Acute myocardial ischemia.\n* Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).\n* Kidney transplant recipients.\n* Serum hemoglobin \\< 9 g\u002FdL.\n* Pregnancy or breastfeeding.\n* History of hypersensitivity to hydrochlorothiazide or furosemide.\n* Patients admitted from the Intensive Care Unit.\n* Patients with recent cardiac surgery (within the last year) or heart transplant recipients.\n* Need for inotropic support to maintain adequate cardiac and\u002For renal output.","ALL","18 Years","100 Years",{"count":20,"type":21},168,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.",[27,28,29,30],"Acute Heart Failure","Congestive Heart Failure","Intraabdominal Hypertension","Cardio-Renal Syndrome",[32,27,33,34,35],"Point of care Ultrasound (POCUS)","Cardio-renal syndrome","Intraabdominal pressure","Diuretic treatment","RECRUITING","2025-06-04",{"date":39,"type":40},"2025-06-06","ACTUAL",{"date":42,"type":40},"2025-03-10",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Instituto de Investigación Sanitaria Aragón","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100513883","comparison-of-bladder-pressure-versus-regional-intestinal-tissue-oxygenation-in-infants-100513883","NCT05971264","Comparison of Bladder Pressure Versus Regional Intestinal Tissue Oxygenation in Infants","BPvsNIRS","Inclusion Criteria:\n\n* Prepped and consented for laparoscopic pyeloplasty or minimal PSARP with perineal or vestibular fistula or lateral thoracotomy for the correction of esophageal atresia\n* Age of 12 months old or less at operation\n* Legal custodian gives consent\n\nExclusion Criteria:\n\n* Anterior abdominal wall thickness greater than 12 mm measured on preoperative MRI imaging if available\n* Patients planned for additional intestinal surgeries or non-standard pyeloplasty, e.g. pyeloplasty with nephrostoma\n* Patients planned for laparoscopic pyeloplasty whose intraoperative urine sample shows pathological results\n* Patients with esophageal atresia who experience pulmonary decompensation and need urgent surgery for fistula clipping",true,"12 Months",{"count":59,"type":21},30,[61],"NA","The goal of this clinical trial is to learn more about intestinal regional oxygen saturation measurements made with near-infrared spectroscopy and bladder pressure measurements in infants without risk of intraabdominal hypertension. The main question it aims to answer is if - in comparison to bladder pressure - the regional intestinal oxygen saturation measured with near-infrared spectroscopy is stable in the muscle-relaxed, intubated patients and the awake and non-sedated patient.\n\nIn case of participation the bladder pressure and the regional intestinal oxygen saturation (measured with near-infrared spectroscopy) will each be measured once intraoperatively and once postoperatively. Patients included in this study will be undergoing an operation which necessitates muscle-relaxation, as well as an indwelling urinary catheter during the operation and for a short-time thereafter for other reasons than this study.",[29,64],"Abdominal Compartment Syndrome",[66,67,34],"Near infra-red spectroscopy","Bladder pressure","2024-04-24",{"date":70,"type":40},"2024-04-25",{"date":72,"type":21},"2024-05-01",{"date":74,"type":21},"2026-06-30",{"name":76,"class":47},"University Children's Hospital, Zurich",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":77},"100365082","fasciotens-to-treat-an-open-abdomen---a-prospective-cohort-study-100365082","NCT04033614","Fasciotens to Treat an Open Abdomen - a Prospective Cohort Study","Fasciotens","Inclusion Criteria:\n\n* Laparostoma with a resorbable net and planned or necessary \"second look\" operation.\n* Age of majority\n* Signed informed consent form or in the case of patients unable to give consent, signature from the authorised representative\u002Flegal carevier or consultant.\n\nExclusion Criteria for the period of use of the Fasciotens Abdomen device:\n\n* Pregnancy or breast-feeding at the time of inclusion into the study\n* A Moribund patient with a life expectancy of less than 24 hours despite laparostomy\n* Unstable thorax or known severe skeletal instability which impaires the use of the fasciotens abdomen device.\n* Open wounds or infections at the potential contact points of the Fasciotens abdomen device\n* Known cardiac insufficiency with ejection fraction less than 35%\n* Patients with lung failure (ARDS) and the need for abdominal positioning within the next 24h\n\nExclusion criteria for the entire duration of the study:\n\n* Persons who are accommodated in a mental hospital or an insititution on official or judicial instruction\n* Persons who are dependent on or have an employment relationship with the principal investigator\n* Other conditions which, at the judgement of the investigator, militate against the use of the investigational product\n* Minority",{"count":86,"type":21},15,[61],"The open abdomen can occur as a result of various diseases. After infections of the abdomen, compartment syndromes or traumata, it is essential for survival (1). This condition of the open abdomen lasts from days to months. Within a very short time, the fascia and abdominal wall structures retract in such a way that direct abdominal closure is often impossible. In addition, there is a pronounced intraabdominal oedema, which additionally increases the space required by the abdominal organs. Therefore, it is clinically indispensable to increase the space of the intraabdominal organs in this life-threatening situation. After the laparotomy (opening of the abdomen) has been performed, it is therefore not closed. However, the natural traction on the abdominal wall, in particular on the fascia, the attached musculature as well as skin and subcutis, no longer exists in this situation. As a result, these structures retract over the period of the existing laparostoma.\n\nIn the present study, the CE-certified medical device Fasciotens Abdomen will be used to prove the functionality of this device and the user feasibility.\n\nThe basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. The possibility to apply a traction to the fascia from the moment of opening the abdomen without reducing the intraabdominal space is absolutely new and the rationale of this technique. The objective of this study is to prove the obvious prevention of fascial retraction through the Fasciotens Abdomen device.",[64,90,29,91],"Pancreatitis,Acute Necrotizing","Peritonitis",[93],"Laparotomy, open abdomen, fascia, retraction, intraabdominal oedema","2023-04-17",{"date":96,"type":40},"2023-04-19",{"date":98,"type":40},"2019-08-05",{"date":100,"type":21},"2026-08",{"name":102,"class":47},"RWTH Aachen University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":132},"100413896","physiologic-signals-and-signatures-with-the-accuryn-monitoring-system---the-accuryn-registry-100413896","NCT04669548","Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry","Physiologic Signals and Signatures With the Accuryn Monitoring System - A Retrospective and Prospective Analysis (The Accuryn Registry)","Inclusion Criteria:\n\n1. Signed or Verbal Informed Consent as required by IRB (if applicable).\n2. Adult (age ≥ 18).\n3. Monitored on the Accuryn® Monitoring System during their procedure and ICU stay (for retrospective enrollment).\n4. Patient is undergoing cardiac surgical intervention(s).\n\nExclusion Criteria:\n\n1. Known history of advanced chronic kidney disease defined by an estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73m2 within 30 days prior to procedure.\n2. The patient is unsuitable for the study, in the opinion of the investigator. This may include vulnerable patient populations such as pregnant women, prisoners ,or those detained in a penal institution.",{"count":111,"type":21},2500,"OBSERVATIONAL","The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.",[29,64,115,116],"Acute Kidney Injury","Cardiovascular Surgery",[118,119,116,120,121,122],"Acute Kidney Injury (AKI)","CABG","Intraabdominal Pressure (IAP)","Urine Output (UO)","Accuryn","2022-09-26",{"date":125,"type":40},"2022-09-28",{"date":127,"type":40},"2020-12-21",{"date":44,"type":21},{"name":130,"class":131},"Potrero Medical","INDUSTRY",9]